If our P2 results are good to outstanding, the race will be on to acquire that IP. If that happens, this will be a summer to remember. The lack of volume lately suggests that lots of shareholders feel the same way; they're holding.
Don’t overlook Gilead business model, find em, like em, buy em. They bought Remdesivir. I think they are trying to work out something with innovations. They are experts in corporate deals. They also specialize in virus therapeutics and cancer treatments ( hummmm ). Read up on Gilead s’ s acquisitions and various leasing models.
Market Data 
Markets 
AI
